|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In this regard, Apatinib or YN968D1, a specific inhibitor of VEGFR-2 has been suggested as a promising therapeutic agent for cancer that can prevent tumor angiogenesis and metastasis.
|
31786193 |
2020 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
However, the clinical efficacy of anti-VEGF/VEGFR therapy is not ideal, prompting the needs to further understand mechanisms behind tumor angiogenesis.
|
30867812 |
2019 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The reasonable designing of multi-target drugs can decrease the side effects and improve the tolerance of antineoplastic agents Studies have identified that VEGFR-2 plays a pivotal role in tumor angiogenesis and drug resistance.
|
30384047 |
2019 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
VEGF-A, VEGF-B, VEGF-R1, VEGFR-2 are key proteins involved in tumor angiogenesis.
|
31322068 |
2019 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Vascular endothelial growth factor receptor 2 (VEGFR2) is an attractive therapeutic target in solid malignancies due to its central role in tumor angiogenesis.
|
31565186 |
2019 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
VEGF/Flk1 Mechanism is Involved in Roxarsone Promotion of Rat Endothelial Cell Growth and B16F10 Xenograft Tumor Angiogenesis.
|
31758020 |
2019 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
A Role of Agrin in Maintaining the Stability of Vascular Endothelial Growth Factor Receptor-2 during Tumor Angiogenesis.
|
31340156 |
2019 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To inhibit tumor-angiogenesis, a physiologically-safe small molecule inhibitor was screened which can potentially interact with kinase domain of VEGFR2 and inhibit its activity.
|
30858542 |
2019 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Vascular endothelial growth factor receptor-2 (VEGFR-2) plays a crucial role in tumor angiogenesis, and inhibition of the VEGFR-2 signaling pathway has already become an attractive approach for cancer therapy.
|
29677483 |
2018 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This review aims to summarize ( a) the up-to-date understanding of the role of VEGF/VEGFR in correlation with proangiogenic mechanisms in various tissues and cells; ( b) the elaboration of antitumor angiogenesis mechanisms of 4 representative TCMs, including Salvia miltiorrhiza, Curcuma longa, ginsenosides, and Scutellaria baicalensis; and ( c) circumstantial clarification of TCM-driven therapeutic actions of suppressing tumor angiogenesis by targeting VEGF/VEGFRs pathway in recent years, based on network pharmacology.
|
29807443 |
2018 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Neutralization of vascular endothelial growth factor receptor 1 (VEGFR1) and/or VEGFR2 is a widely used means of inhibiting tumor angiogenesis.
|
30251659 |
2018 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Vascular endothelial growth factor receptor-2 (VEGFR-2) plays a crucial role in tumor angiogenesis, and inhibition of the VEGFR-2 signaling pathway has emerged as an attractive target for cancer therapy.
|
30108994 |
2018 |
|
Tumor Angiogenesis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The proximal promoter of <i>VEGFR-2</i> contains a G-quadruplex, which has been suggested to interact with small molecules that inhibit <i>VEGFR-2</i> expression and thereby tumor angiogenesis.However, its structure is not known.
|
29666187 |
2018 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Nintedanib, a potent triple angiokinase inhibitor, targets PDGFR, VEGFR, and FGFR pathways critical for tumor angiogenesis and vasculature.
|
30166401 |
2018 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our results suggest that inhibition of tumor angiogenesis via the suppression VEGFR2 phosphorylation may be one of the underlying mechanisms by which OA exerts its anti-cancer effect.
|
29065844 |
2018 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These studies reveal previously unrecognized Vegfr2 gene dosage effects in tumor angiogenesis and a lack of synergy between VEGFR2 and endothelial FGFR1/2 signaling during tumor growth.
|
30283071 |
2018 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Characterization of novel pathways that act in parallel with the VEGF/VEGFR axis to promote tumor angiogenesis may provide insights into novel anti-angiogenic therapeutic targets.
|
30019429 |
2018 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Glycosylation controls cooperative PECAM-VEGFR2-β3 integrin functions at the endothelial surface for tumor angiogenesis.
|
29717262 |
2018 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
VEGFR2 (vascular endothelial growth factor receptor 2) is the main trigger of VEGF-mediated angiogenic signal and targeting VEGFR2 pathway to inhibit tumor angiogenesis represents a promising strategy for cancer therapy.
|
29408327 |
2018 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors (VEGFRs) play a central role in tumor angiogenesis and represent potential targets for anticancer therapy.
|
29849960 |
2018 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In human, the interaction between vascular endothelial growth factor (VEGF) and its receptor (VEGFR2) is critical for tumor angiogenesis.
|
30467531 |
2018 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
|
29545238 |
2018 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Dual-Targeted Microbubbles Specific to Integrin αVβ3 and Vascular Endothelial Growth Factor Receptor 2 for Ultrasonography Evaluation of Tumor Angiogenesis.
|
29706409 |
2018 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Cooperation between VEGFR2 and integrin αVβ3 is critical for neovascularization in wound healing, cardiovascular ischemic diseases, ocular diseases, and tumor angiogenesis.
|
30036530 |
2018 |
|
Tumor Angiogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The aim of this study is to test the therapeutic efficacy and targeting specificity of a chemically-synthesized peptide, UPI, which compete for epsin binding sites in VEGFR2 and potentially inhibits Epsin-VEGFR2 interaction in vivo, in an attempt to reproduce an epsin-deficient phenotype in tumor angiogenesis.
|
29357089 |
2018 |